{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:16:22Z","timestamp":1784200582961,"version":"3.55.0"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,2,10]]},"DOI":"10.18632\/oncotarget.28193","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:18:04Z","timestamp":1644499084000},"page":"319-330","source":"Crossref","is-referenced-by-count":14,"title":["ABT199\/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells"],"prefix":"10.18632","volume":"13","author":[{"given":"Benigno C.","family":"Valdez","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[{"name":"Division\/Department of Experimental Oncology, University of Alberta\/Cross Cancer Institute, Edmonton T6G 1Z2, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","article-title":"Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation","volume":"3","author":"Michallet","year":"2013","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"10","author":"Ferrant","year":"2007","journal-title":"Blood"},{"key":"3","first-page":"1065","article-title":"S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine","volume":"6","author":"Plunkett","year":"2001","journal-title":"Cancer Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/em.20603","article-title":"Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies","volume":"5","author":"Andersson","year":"2010","journal-title":"Environ Mol Mutagen"},{"key":"5","first-page":"16617","article-title":"Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity","volume":"26","author":"Plunkett","year":"1990","journal-title":"J Biol Chem"},{"key":"6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1517\/17425255.2013.737319","article-title":"Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan","volume":"9","author":"Paci","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"1","author":"Shpall","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis","volume":"5","author":"Ram","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"5","author":"Kebriaei","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"1","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Galinsky","year":"2014","journal-title":"Cancer Discov"},{"key":"12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exphem.2020.01.003","article-title":"Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells","volume":"8","author":"Andersson","year":"2020","journal-title":"Exp Hematol"},{"key":"13","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"10","author":"Stein","year":"2018","journal-title":"Haematologica"},{"key":"14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"13","author":"Chyla","year":"2019","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.leukres.2008.01.016","article-title":"Altered gene expression in busulfan-resistant human myeloid leukemia","volume":"3","author":"Andersson","year":"2008","journal-title":"Leuk Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2165\/00003088-200038040-00001","article-title":"Metabolism and pharmacokinetics of oxazaphosphorines","volume":"3","author":"Yule","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.exphem.2018.08.002","article-title":"Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells","volume":"6","author":"Andersson","year":"2018","journal-title":"Exp Hematol"},{"key":"18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"2","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-6-15","article-title":"Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study","volume":"6","author":"Guo","year":"2013","journal-title":"J Hematol Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"1","author":"Chiusolo","year":"2015","journal-title":"Lancet Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"12","author":"Benoit","year":"2014","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"27946","DOI":"10.18632\/oncotarget.8547","article-title":"High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition","volume":"7","author":"Dolman","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/284555a0","article-title":"Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation","volume":"28","author":"Wyllie","year":"1980","journal-title":"Nature"},{"key":"24","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/leu.2015.99","article-title":"Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1","volume":"2","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"key":"25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"2","author":"McCubrey","year":"2012","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1038\/sj.onc.1208069","article-title":"Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis","volume":"2","author":"Auberger","year":"2004","journal-title":"Oncogene"},{"key":"27","doi-asserted-by":"publisher","first-page":"26365","DOI":"10.1074\/jbc.m010101200","article-title":"Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1","volume":"27","author":"Johnson","year":"2001","journal-title":"J Biol Chem"},{"key":"28","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1074\/jbc.m112355200","article-title":"Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes","volume":"27","author":"Izumo","year":"2002","journal-title":"J Biol Chem"},{"key":"29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"Thompson","year":"2008","journal-title":"Cell Metab"},{"key":"30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4149\/gpb_2017026","article-title":"ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells","volume":"3","author":"Choi","year":"2018","journal-title":"Gen Physiol Biophys"},{"key":"31","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1242\/jcs.01540","article-title":"The AMP-activated protein kinase pathway--new players upstream and downstream","volume":"11","author":"Hardie","year":"2004","journal-title":"J Cell Sci"},{"key":"32","doi-asserted-by":"publisher","first-page":"16345","DOI":"10.1074\/jbc.M001458200","article-title":"Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential","volume":"27","author":"Bommert","year":"2000","journal-title":"J Biol Chem"},{"key":"33","doi-asserted-by":"publisher","first-page":"a008011","DOI":"10.1101\/cshperspect.a008011","article-title":"Wnt signaling in normal and malignant hematopoiesis","volume":"5","author":"Reya","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"34","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1158\/0008-5472.CAN-07-5558","article-title":"C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine","volume":"6","author":"Sansom","year":"2008","journal-title":"Cancer Res"},{"key":"35","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.2147\/CMAR.S210504","article-title":"ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway","volume":"1","author":"Li","year":"2019","journal-title":"Cancer Manag Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1073\/pnas.96.4.1603","article-title":"Target genes of beta-catenin-T cell-factor\/lymphoid-enhancer-factor signaling in human colorectal carcinomas","volume":"9","author":"Hanski","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","article-title":"The Wnt\/\u03b2-catenin pathway in ovarian cancer: a review","volume":"13","author":"Buchsbaum","year":"2013","journal-title":"Gynecol Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates","volume":"1","author":"Loh","year":"2008","journal-title":"Cancer Cell"},{"key":"39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40591-015-0040-8","article-title":"Outlook on PI3K\/AKT\/mTOR inhibition in acute leukemia","volume":"3","author":"Baldus","year":"2015","journal-title":"Mol Cell Ther"},{"key":"40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"12","author":"Loh","year":"2012","journal-title":"Blood"},{"key":"41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bcp.2010.09.027","article-title":"The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling","volume":"8","author":"Andersson","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2164-15-74","article-title":"Comprehensive analysis of \u03b2-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt\/\u03b2-catenin signaling","volume":"1","author":"Kolligs","year":"2014","journal-title":"BMC Genomics"},{"key":"43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1042\/CS20110625","article-title":"AMP-activated protein kinase, stress responses and cardiovascular diseases","volume":"12","author":"Zou","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"44","first-page":"1692","article-title":"STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients","volume":"8","author":"Prin","year":"1996","journal-title":"Blood"},{"key":"45","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/1535-7163.MCT-11-0850","article-title":"JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells","volume":"1","author":"Kawauchi","year":"2012","journal-title":"Mol Cancer Ther"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:18:08Z","timestamp":1644499088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2,10]]}},"alternative-id":["28193"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28193","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}